|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX17
|
|
gptkbp:brand
|
gptkb:Hycamtin
|
|
gptkbp:CASNumber
|
gptkb:123948-87-8
|
|
gptkbp:developedBy
|
gptkb:camptothecin
|
|
gptkbp:discoveredBy
|
gptkb:SmithKline_Beecham
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C23H23N3O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
topotecan
|
|
gptkbp:KEGGID
|
gptkb:D02370
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
topoisomerase I inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL428
gptkb:DB00350
60700
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
fatigue
neutropenia
thrombocytopenia
|
|
gptkbp:synonym
|
gptkb:NSC_609699
gptkb:SKF_104864-A
|
|
gptkbp:UNII
|
YGJ1F93G8W
|
|
gptkbp:usedFor
|
gptkb:cancer
Small Cell Lung Cancer
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
gptkb:camptothecin
|
|
gptkbp:bfsLayer
|
6
|